연구성과로 돌아가기

2021 연구성과별 연구자 정보 (232 / 2991)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Atherosclerotic Burden and Vascular Risk in Stroke Patients With Atrial Fibrillation Yu, Sungwook Yu, S 16 Korea Univ, Anam Hosp, Dept Neurol, Coll Med, Seoul, South Korea jhpark619@hanyang.ac.kr;mcastenosis@gmail.com;
Atherosclerotic Burden and Vascular Risk in Stroke Patients With Atrial Fibrillation Park, Kwang Yeol Park, KY 17 Chung Ang Univ, Dept Neurol, Coll Med, Seoul, South Korea jhpark619@hanyang.ac.kr;mcastenosis@gmail.com;
Atherosclerotic Burden and Vascular Risk in Stroke Patients With Atrial Fibrillation Kim, Jeong-Min Kim, JM 18 Seoul Natl Univ Hosp, Dept Neurol, Seoul, South Korea ABH-2469-2021 Kim, Jeong-Min 0000-0001-7213-5527 Kim, Jeong-Min jhpark619@hanyang.ac.kr;mcastenosis@gmail.com;
Atherosclerotic Burden and Vascular Risk in Stroke Patients With Atrial Fibrillation Choi, Jay Chol Choi, JC 19 Jeju Natl Univ, Dept Neurol, Jeju City, South Korea O-5940-2014 choi, jo jhpark619@hanyang.ac.kr;mcastenosis@gmail.com;
Atherosclerotic Burden and Vascular Risk in Stroke Patients With Atrial Fibrillation Seo, Woo-Keun Seo, WK 20 교신저자 Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea jhpark619@hanyang.ac.kr;mcastenosis@gmail.com;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Quinn, D., I Quinn, DI 1 교신저자 USC, Keck Sch Med, Div Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Ng, C. F. Ng, CF 2 Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China E-5134-2011 Ng, Chi-Fai diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Grande, E. Grande, E 3 MD Anderson Canc Ctr, Dept Med Oncol, Madrid, Spain diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Kwon, T. G. Kwon, TG 4 Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Linke, R. Linke, R 5 SFJ Pharmaceut, Pleasanton, CA USA diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Lee, J-L Lee, JL 6 Univ Ulsan, Asian Med Ctr, Dept Med Oncol, Coll Med, Seoul, South Korea AGI-4843-2022 Lee, Jae Lyun diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Rosbrook, B. Rosbrook, B 7 Pfizer Oncol, New York, NY USA diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Thakur, M. N. Thakur, MN 8 Pfizer, Sandwich, Kent, England diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Eto, M. Eto, M 9 Kyushu Univ, Dept Urol, Fukuoka, Fukuoka, Japan diquinn@med.usc.edu;
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups Gross-Goupil, M. Gross-Goupil, M 10 Ctr Hosp Univ Bordeaux, Dept Med Oncol, Bordeaux, France diquinn@med.usc.edu;
페이지 이동: